The United States Food and Drug Administration (U.S. FDA) has approved commercial marketing and distribution of cheap version of Lithium Carbonate capsules, manufactured by Glenmark Generics Inc (GGI), the US subsidiary of Glenmark Generics, in the US market. The company said, in a media release, that it would soon start marketing of capsules in 150 mg, 300 mg and 600 mg range.
 
Lithium Carbonate is used for the treatment of Bipolar Disorder by decreasing the frequency and causes of manic. The drug may produce results within 1 to three weeks. Manic symptoms include motor hyperactivity, reduced need for sleep, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility which can lead to many physiological disorders.
 
Sales of Lithium Carbonate capsules stood at USD 10 million by the end of September 2008. Glenmark Generics is already authorized to distribute 38 generic products in the US market with over 40 ANDA's are still pending for approval from U.S. FDA. The company is also eyeing on external development partnerships with some firms to accelerate its growth in the generic drug segment.